Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Randomized, Phase II Clinical Trial

NCT07619911 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07619911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Randomized, Phase II Clinical Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
December 31, 2030
Enrollment
84 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chemoradiotherapy, nsclc stage iii, shr-1701